BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 23, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2020

View Archived Issues

Just the vesicles, please

Read More

Monocytes have it both ways in DMD

Read More

A role for DICER1 deficiency in retinal pigmented epithelium degeneration and neovascularization

Read More

New simulation approach for prediction of nanomedicine transport and distribution in animal species

Read More

PI4KIIIb-dependent secretion plays a role in the progression of chromosome 1q-amplified cancers

Read More

Enrolment update for phase III study of emixustat in Stargardt disease

Read More

Phase I study of brilacidin for ulcerative colitis meets primary endpoints

Read More

Discovery of new PROTAC with improved PK properties

Read More

First-in-human data presented for m102.4

Read More

Modified cyclodextrins show promising activity against multiple viral infections

Read More

Phase I/II data presented for SHR-3680 in metastatic castration-resistant prostate cancer

Read More

Focused ultrasound enhances BBB delivery of TrkA receptor ligands for treating neurodegeneration

Read More

Role of microglia in memory loss elucidated

Read More

MedImmune presents phase I data on MEDI-3726 in patients with mCRPC

Read More

IMP-4297 studied in phase III as maintenance treatment for advanced ovarian cancer

Read More

XyloCor begins first-in-human study of XC-001 gene therapy for refractory angina

Read More

Arcus Biosciences divulges adenosine A2A and/or A2B receptor antagonists

Read More

Fujifilm describes new compounds for adenovirus infections

Read More

BioBlocks and Visionary Pharmaceuticals disclose SGK1 inhibitors

Read More

Cocrystal Pharma identifies influenza PB2 inhibitors

Read More

Arbutus Biopharma synthesizes new compounds for HBV

Read More

Zhittya cleared to begin phase I study in Mexico with novel biological drug for Parkinson's

Read More

Eisai to withdraw Belviq from U.S. market

Read More

China NMPA approves Tecentriq with chemotherapy for extensive-stage SCLC

Read More

Japanese P-DRIVE study of polatuzumab vedotin in DLBCL meets primary endpoint

Read More

Phase II study of ANVS-401 in Alzheimer's cleared by DSMB to continue

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 22, 2025.
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing